Asset Details
Do you wish to reserve the book?
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Do you wish to request the book?
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
2014
Overview
The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin’s lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies.
Publisher
Springer Japan,Springer Nature B.V
Subject
/ Hematologic Neoplasms - genetics
/ Hematologic Neoplasms - immunology
/ Hematologic Neoplasms - therapy
/ Humans
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - immunology
/ Leukemia, Myeloid, Acute - therapy
/ Medicine
/ Multiple Myeloma - immunology
/ Oncology
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy
/ Receptors, Antigen - genetics
/ Receptors, Antigen - immunology
/ Receptors, Antigen - metabolism
/ Recombinant Fusion Proteins - genetics
/ Recombinant Fusion Proteins - immunology
